-
1 Comment
Advicenne S.A is currently in a long term downtrend where the price is trading 31.4% below its 200 day moving average.
From a valuation standpoint, the stock is 84.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.8.
Based on the above factors, Advicenne S.A gets an overall score of 1/5.
ISIN | FR0013296746 |
---|---|
Sector | Healthcare |
Exchange | PA |
CurrencyCode | EUR |
Industry | Pharmaceuticals |
Target Price | 20.95 |
---|---|
Market Cap | 65M |
Dividend Yield | 0.0% |
Beta | 1.43 |
PE Ratio | None |
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ADVIC.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025